Sana Biotechnology

NSQ:SANA · US7995661045

BiotechnologySmall

360° View

Value81

Price/Sales—

Price/Earnings60

Price/Book95

Dividend Yield1

Growth52

Revenue Growth—

Profit Growth33

Capital Growth78

TSR 52w27

Safety37

Leverage15

Liquidity97

Refinancing19

Combined67

Sentiment33

Analyst Opinions28

Pro Holdings53

Opinion Changes50

Market Pulse35

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2018

Employees235

Websitesana.com

ISINUS7995661045

Last UpdateApr 2, 2026

Index & Theme

Stem Cell TherapyEndocrinologyHealth DiagnosticsDiabetesGeneticsHematologyImmunologyOncologyBiotechnologyHealth CareLife ScienceProduct Research

Description

Sana Biotechnology, Inc. (Sana) operates as a biotechnology company focusing on utilizing engineered cells as medicines. For the company's ex vivo platform, the company has made focused investments in its hypoimmune platform technology, which it ref…

Analysis

Sana Biotechnology's 360° View rank of 63 places it above its peer average — better than 63% of its true peers.

It's growing solidly (52) and looks cheap versus peers (81). On safety it is carrying more balance-sheet risk (37), and the market shows muted sentiment (33). Taken together, its Combined rank of 67 reads as above its peer average.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Sana Biotechnology with its peers

Fate Therapeutics

NMQ:FATE

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Arcellx

NSQ:ACLX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Nkarta

NSQ:NKTX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Kyverna Therapeutics

NSQ:KYTX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Forte Biosciences

NAQ:FBRX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Caribou Biosciences

NSQ:CRBU

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →